IP Verse

Type Ii Anti-Cd20 Antibody For Reducing Formation Of Anti-Drug Antibodies - EP3387015

The patent EP3387015 was granted to F Hoffmann LA Roche on Oct 27, 2021. The application was originally filed on Dec 6, 2016 under application number EP16810283A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3387015

F HOFFMANN LA ROCHE
Application Number
EP16810283A
Filing Date
Dec 6, 2016
Status
Granted And Under Opposition
Sep 24, 2021
Grant Date
Oct 27, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANJul 26, 2022GREAVES BREWSTERADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTWO2009134738
INTERNATIONAL-SEARCH-REPORTWO2012107417
INTERNATIONAL-SEARCH-REPORTWO2012117002
INTERNATIONAL-SEARCH-REPORTWO2014056783
INTERNATIONAL-SEARCH-REPORTWO2015095410
OPPOSITIONUS2010003252

Non-Patent Literature (NPL) Citations (27) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
INTERNATIONAL-SEARCH-REPORT- Cb Siegall ET AL, "Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy", The Journal of Immunology, UNITED STATES, (19971115), pages 5168 - 5173, URL: http://www.jimmunol.org/content/159/10/5168.full.pdf#page=1&view=FitH, (20160420), XP055266904 [A] 1-23 * abstract *-
INTERNATIONAL-SEARCH-REPORT- CIARA L FREEMAN ET AL, "Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions", BLOOD, (20151210), vol. 126, no. 24, pages 2646 - 2649, XP055389665 [IP] 1-23 * pages 2646-2648 *-
INTERNATIONAL-SEARCH-REPORT- FREEMAN CIARA LOUISE ET AL., "Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR)", BLOOD, 56TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2014, (201412), vol. 124, no. 21, XP009194886 [I] 1-23 * abstract *-
INTERNATIONAL-SEARCH-REPORT- XU XIAO-JUN ET AL, "Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells", CANCER LETTERS, NEW YORK, NY, US, (20131016), vol. 343, no. 2, doi:10.1016/J.CANLET.2013.10.004, ISSN 0304-3835, pages 172 - 178, XP028814569 [A] 1-23 * page 176 *
INTERNATIONAL-SEARCH-REPORT- FREEMAN C, "Cytokine release in patients treated with obinutuzumab, a glycoengineered type II anti-CD20 antibody and possible relationship with development of infusion related reactions in patients with chronic lymphocytic leukaemia", BRITISH JOURNAL OF HAEMATOLOGY, 54TH ANNUAL SCIENTIFIC MEETING OF THE BRITISH-SOCIETY-FOR-HAEMATOLOGY; BIRMINGHAM, UK; APRIL 28 -30, 2014, (201405), vol. 165, no. Suppl. 1, Sp. Iss. SI, page 70, XP009194890 [I] 1-23 * abstract *
INTERNATIONAL-SEARCH-REPORT- FREEMAN, C, MORSCHAUER F ET AL., "Pattern of cytokine release in patients with chronic lymphocytic leukaemia treated with obinutuzumab and possible relationship with development of infusion related reactions (IRR)", BRITISH JOURNAL OF HAEMATOLOGY, 55TH ANNUAL SCIENTIFIC MEETING OF THE BRITISH-SOCIETY-FOR-HAEMATOLOGY; EDINBURGH, UK; APRIL 20 -22, 2015, (201504), vol. 169, no. Suppl. 1, Sp. Iss. SI, page 64, XP009194888 [I] 1-23 * abstract *
INTERNATIONAL-SEARCH-REPORT- M. E. MOSSOBA ET AL, "Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts", CLINICAL CANCER RESEARCH, US, (20110426), vol. 17, no. 11, doi:10.1158/1078-0432.CCR-11-0493, ISSN 1078-0432, pages 3697 - 3705, XP055266902 [A] 1-23 * abstract *
INTERNATIONAL-SEARCH-REPORT- HASSAN RAFFIT ET AL, "Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20040116), vol. 10, no. 1 Pt 1, doi:10.1158/1078-0432.CCR-1160-3, ISSN 1078-0432, pages 16 - 18, XP002547018 [Y] 1-11 * abstract *
INTERNATIONAL-SEARCH-REPORT- M. ONDA ET AL, "Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts", THE JOURNAL OF IMMUNOLOGY, US, (20140602), vol. 193, no. 1, doi:10.4049/jimmunol.1400063, ISSN 0022-1767, pages 48 - 55, XP055266908 [A] 1-23 * abstract *
INTERNATIONAL-SEARCH-REPORT- CHRISTIAN KLEIN ET AL, "Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties", MABS, (20130101), vol. 5, no. 1, doi:10.4161/mabs.22771, ISSN 1942-0862, pages 22 - 33, XP055117097 [A] 1-23 * abstract figures *
INTERNATIONAL-SEARCH-REPORT- MARINUS H. J. VAN OERS, "CD20 antibodies: type II to tango?", BLOOD, (20150531), vol. 119, doi:http://dx.doi.org/10.1182/blood-2012-04-420711, pages 5061 - 5063, XP055266601 [A] 1-23 * pages 5061-5062 *
OPPOSITION- Klein Christian; Waldhauer Inja; Nicolini Valeria; Dunn Claire; Grundschober Anne Freimoser; Danny Gerrits; Boerman Otto; Nayak Tapan; Herter Sylvia; Van Puijenbroeki Erwin; Ast Oliver; Hofer Thomas; Hosse Ralf; Lang Sabine; Neumann Sebastian; Kettenbergeris Hubert; Neubauer Markus; Gorr Ingo; Tuerck Dietrich; Evers Stefan; Gerdes Christian; Levitsky Victor; Bacac Marina; Moessner Ekkehard; Umana Pablo, "Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer", Blood, American Society of Hematology, US, US , (20131115), vol. 122, no. 21, ISSN 0006-4971, page 2278, XP008184438-
OPPOSITION- Van Brummelen Emilie M J, Ros Willeke, Wolbink Gertjan, Beijnen Jos H, Schellens Jan H M, "Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges", The Oncologist, (20161001), vol. 21, no. 10, pages 1260 - 1268, XP055950854-
OPPOSITION- Osada T, Patel S P, Hammond S A, Osada K, Morse M A, Lyerly H K, "CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.", Cancer Immunology, Immunotherapy, Springer, Berlin, DE, Berlin, DE , (20150601), vol. 64, no. 6, doi:10.1007/s00262-015-1671-y., ISSN 1432-0851, pages 677 - 688, XP002753474
OPPOSITION- Teichgräber Volker, Monasterio Carmen, Chaitanya Krishna, Boger Regina, Gordon Katrin, Dieterle Thomas, Jäger Dirk, Bauer Stefan, "Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro", ADVANCES IN MEDICAL SCIENCES, Uniwersytet Medyczny w Bialymstoku, PL, PL , (20150901), vol. 60, no. 2, doi:10.1016/j.advms.2015.04.006, ISSN 1896-1126, pages 264 - 272, XP055950860
OPPOSITION- Swann, P.G. ; Tolnay, M. ; Muthukkumar, S. ; Shapiro, M.A. ; Rellahan, B.L. ; Clouse, K.A., "Considerations for the development of therapeutic monoclonal antibodies", Current Opinion in Immunology, ELSEVIER, OXFORD., GB, GB , (20080801), vol. 20, no. 4, doi:10.1016/j.coi.2008.05.013, ISSN 0952-7915, pages 493 - 499, XP023612050
OPPOSITION- Bacac Marina, Fauti Tanja, Colombetti Sara, Sam Johannes, Nicolini Valeria, Steinhoff Nathalie, Ast Oliver, Bruenker Peter, Hosse Ralf, Hofer Thomas, Moessner Ekkehard, Jaeger Christiane, Saro Jose, Karanikas Vaios, Klein Christian, Umaña Pablo, "ITOC2 - 037. CEA TCB, A novel T-cell bispecific antibody with potent in vitro and in vivo antitumour activity against solid tumours", European Journal of Cancer, Elsevier, Amsterdam NL, Amsterdam NL , (20150301), vol. 51, doi:10.1016/j.ejca.2015.01.051, ISSN 0959-8049, page S13, XP055950857
OPPOSITION- Hay Charles, Recht Michael, Carcao Manuel, Reipert Birgit, "Current and Future Approaches to Inhibitor Management and Aversion", SEMINARS IN THROMBOSIS AND HEMOSTASIS, Thieme Medical Publishers, Inc., US, US , (20060601), vol. 32, no. S 2, doi:10.1055/s-2006-946910, ISSN 0094-6176, pages 15 - 21, XP055950843
OPPOSITION- Farrell R. A., Marta M., Gaeguta A. J., Souslova V., Giovannoni G., Creeke P. I., "Development of resistance to biologic therapies with reference to IFN- beta", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, LONDON, GB, GB , (20120401), vol. 51, no. 4, doi:10.1093/rheumatology/ker445, ISSN 1462-0324, pages 590 - 599, XP055950846
OPPOSITION- COLLINS P W ET AL, "Rituximab and immune tolerance in severe hemophilia A: A consecutive national cohort", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, BLACKWELL PUBLISHING, OXFORD, GB, GB , (20090501), vol. 7, no. 5, doi:10.1111/j.1538-7836.2009.03332.x, ISSN 1538-7933, pages 787 - 794, XP002619265
OPPOSITION- HASSAN RAFFIT; WILLIAMS-GOULD JUANITA; WATSON THELMA; PAI-SCHERF LEE; PASTAN IRA, "Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.", Clinical Cancer Research, Association for Cancer Research, US, US, (20040116), vol. 10, no. 1 Pt 1, doi:10.1158/1078-0432.CCR-1160-3, ISSN 1078-0432, pages 16 - 18, XP002547018
OPPOSITION- M. Bacac, T. Fauti, J. Sam, S. Colombetti, T. Weinzierl, D. Ouaret, W. Bodmer, S. Lehmann, T. Hofer, R. J. Hosse, E. Moessner, O. Ast, P. Bruenker, S. Grau-Richards, T. Schaller, A. Seidl, C. Gerdes, M. Perro, V. Nicolini, N. Steinhoff, S. Dudal, S. Neumann, T. Von Hirschheydt, C. Jaeger, J. Saro, V. Karanikas, C. Klein, P. Umana, "A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors", Clinical Cancer Research, Association for Cancer Research, US, US, (20160701), vol. 22, no. 13, doi:10.1158/1078-0432.CCR-15-1696, ISSN 1078-0432, pages 3286 - 3297, XP055522007
OPPOSITION- Beers Stephen A., Chan Claude H. T., James Sonya, French Ruth R., Attfield Kathrine E., Brennan Claire M., Ahuja Anupama, Shlomchik Mark J., Cragg Mark S., Glennie Martin J., "Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation", Blood, American Society of Hematology, US, US , (20081115), vol. 112, no. 10, doi:10.1182/blood-2008-04-149161, ISSN 0006-4971, pages 4170 - 4177, XP055950848
OPPOSITION- E. Mossner, P. Brunker, S. Moser, U. Puntener, C. Schmidt, S. Herter, R. Grau, C. Gerdes, A. Nopora, E. Van Puijenbroek, C. Ferrara, P. Sondermann, C. Jager, P. Strein, G. Fertig, T. Friess, C. Schull, S. Bauer, J. Dal Porto, C. Del Nagro, K. Dabbagh, M. J. S. Dyer, S. Poppema, C. Klein, P. Umana, "Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity", Blood, (20100603), vol. 115, no. 22, doi:10.1182/blood-2009-06-225979, ISSN 00064971, pages 4393 - 4402, XP055190313
OPPOSITION- Umana Pablo, Moessner Ekkehard, Bruenker Peter, Unsin Gabriele, Puentener Ursula, Suter Tobias, Grau Roger, Schmidt Carla, Gerdes Christian, Nopora Adam, Patre Monika, Moser Samuel, Sondermann Peter, Wheat Luise, Dyer Martin J.S., Poppema Sibrand, Bauer Sabine, Strein Pamela, Friess Thomas, Klein Christian, "Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.", Blood, American Society of Hematology, US, US , (20061116), vol. 108, no. 11, doi:10.1182/blood.V108.11.229.229, ISSN 0006-4971, pages 229 - 229, XP055950851
OPPOSITION- Narendra Chirmule; Vibha Jawa; Bernd Meibohm, "Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy", AAPS JOURNAL, AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS, US, US , (20120310), vol. 14, no. 2, doi:10.1208/s12248-012-9340-y, ISSN 1550-7416, pages 296 - 302, XP035043118
OPPOSITION- Lindsey M. Hoffman, Lia Gore, "Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications", Frontiers in Oncology, (201403), vol. 4, doi:10.3389/fonc.2014.00063, pages 1 - 5, XP055548630

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents